This opportunity funds early stage testing of pharmacologic or neuromodulatory device-based interventions targeting mental disorders. It requires an experimental therapeutics approach that evaluates both clinical effects and mechanisms of action through clinical trials. The focus is on interventions with novel mechanisms, using protocol designs that test dose-dependent neurophysiological, clinical, or behavioral effects to inform treatment development.
Eligible applicants include a wide range of U.S. entities such as public and private institutions of higher education, government entities at various levels, nonprofits, small businesses, and tribal organizations. Specific eligibility details are provided in the full announcement.
